Pulsed Field Ablation (PFA) is a non-thermal energy source that has the potential to transform the cardiac ablation landscape. In this five-part micro-documentary series, four European physicians share their experiences with FARAPULSE™ Pulsed Field Ablation and the FARAWAVE™ catheter. Through their insights, viewers will discover how PFA can positively impact clinical practice and enhance the atrial fibrillation (AF) ablation experience for patients.
Interested in learning why cell selective energy delivery matters? In this episode Prof Julian Chun delves into the science behind irreversible electroporation and explains how FARAPULSE PFA energy delivery targets the cardiomyocyte, sparing the esophageal and endothelial cells. This cell selective energy delivery reduces typical thermal complications, making PFA a promising new chapter in EP.
What about FARAPULSE and more specifically the FARAWAVE PFA catheter, leads to a highly predictable workflow and durable pulmonary vein isolation? Prof Boris Schmidt discusses how the purpose-built FARAWAVE catheter with an over-the-wire design is translating to rapid, reproducible and predictable procedure times with a short operator learning curve.
How does the FARAPULSE cell selective energy delivery with an optimised workflow and purpose-built catheter translate to clinical practice? Dr Yuri Blaauw discusses how FARAPULSE has changed his clinical practice and hospital workflow. The predictable procedure times with FARAPULSE PFA have allowed for treatment of more patients per day. Learn from him how this has also impacted his hospital capacity.
How has FARAPULSE transformed the ablation patient experience? Prof Mattias Duytschaever often gets asked by his patients ‘Doctor, did you treat me, I feel no pain?’. His patients being treated with FARAPULSE PFA often experience no chest discomfort post-procedure.
Additionally, hear how FARAPULSE has provided peace of mind for both the physician and the patient in being able to offer an ablation technology with no reported rare catastrophic injuries associated with thermal ablation.
With the platform versatility and ability to create non-thermal irreversible lesions, what does the future hold for FARAPULSE™ PFA? The series concludes with the physicians discussing the importance of randomised clinical trials and large real-world registries to make informed decisions on therapy choice. Additionally, the benefits of early rhythm control to limit atrial fibrillation progression and the possibility of new patient populations being treated with what might be, the optimal energy source for cardiac ablation.